Royal Bank of Canada’s Verona Pharma VRNA Stock Holding History

Royal Bank of Canada’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,075	Closed	-$221K	–	7681
2025 Q3	$221K	Sell	2,075 -4,378	-68%	-$457K	﹤0.01%	5032
2025 Q2	$609K	Sell	6,453 -3,266	-34%	-$242K	﹤0.01%	4309
2025 Q1	$617K	Buy	9,719 +2,938	+43%	+$176K	﹤0.01%	3837
2024 Q4	$315K	Buy	6,781 +5,280	+352%	+$198K	﹤0.01%	4442
2024 Q3	$43K	Sell	1,501 -32	-2%	-$788	﹤0.01%	5778
2024 Q2	$21K	Sell	1,533 -26	-2%	-$380	﹤0.01%	6066
2024 Q1	$25K	Buy	1,559 +58	+4%	+$1K	﹤0.01%	5833
2023 Q4	$30K	Sell	1,501 -2	-0.1%	-$30	﹤0.01%	6191
2023 Q3	$24K	Sell	1,503 -72	-5%	-$1.39K	﹤0.01%	6120
2023 Q2	$34K	Sell	1,575 -167	-10%	-$3.56K	﹤0.01%	5965
2023 Q1	$35K	Buy	1,742 +10	+0.6%	+$216	﹤0.01%	5806
2022 Q4	$45K	Buy	1,732 +1,006	+139%	+$13.4K	﹤0.01%	5948
2022 Q3	$7K	Buy	+726	New	+$6.12K	﹤0.01%	6619

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Royal Bank of Canada's VRNA Position: Q4 2025 in Review

Royal Bank of Canada sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 2,075 shares — an estimated $221K sold.

Royal Bank of Canada first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $617K in Q1 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Royal Bank of Canada reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Royal Bank of Canada sold 2,075 Verona Pharma shares in Q4 2025, an estimated $221K.
Royal Bank of Canada first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
Royal Bank of Canada's Verona Pharma position peaked at $617K in Q1 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.